Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

Journal of Gastroenterology

Volumn 46, Issue 1, 2011, Pages 92-100

  Tateyama, Masakuni ^a,b   Yatsuhashi, Hiroshi ^a   Taura, Naota ^a   Motoyoshi, Yasuhide ^a   Nagaoka, Shinya ^a   Yanagi, Kenji ^a   Abiru, Seigo ^a   Yano, Koji ^a   Komori, Atsumasa ^a   Migita, Kiyoshi ^a   Nakamura, Minoru ^a   Nagahama, Hiroyasu ^b   Sasaki, Yutaka ^b   Miyakawa, Yuzo ^c   Ishibashi, Hiromi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c Miyakawa Memorial Research Foundation   (Japan)

Author keywords

Alpha fetoprotein; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS C VIRUS CORE ANTIGEN; INTERFERON; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER INCIDENCE; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; STAGING; THROMBOCYTE COUNT;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 78651511517     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0293-6     Document Type: Article

References (55)

1. NH Afdhal 2004 The natural history of hepatitis C Semin Liver Dis 24 Suppl 2 3 8 10.1055/s-2004-832922 15346240
2. J Cohen 2005 Virology. Culture systems for hepatitis C virus in sight at last Science 308 1539 1541 1:CAS:528:DC%2BD2MXlt1Snsro%3D 10.1126/science.308. 5728.1539 15947152
3. M Sherman 2005 Hepatocellular carcinoma: epidemiology, risk factors, and screening Semin Liver Dis 25 143 154 10.1055/s-2005-871194 15918143
4. MJ Alter 2007 Epidemiology of hepatitis C virus infection World J Gastroenterol 13 2436 2441 17552026
5. HB El-Serag KL Rudolph 2007 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557 2576 1:CAS:528: DC%2BD2sXnvFOgsrw%3D 10.1053/j.gastro.2007.04.061 17570226
6. H Yoshida Y Shiratori M Moriyama Y Arakawa T Ide M Sata, et al. 1999 Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy Ann Intern Med 131 174 181 1:CAS:528:DyaK1MXlsVCrtbo%3D 10428733
7. TJ Liang T Heller 2004 Pathogenesis of hepatitis C-associated hepatocellular carcinoma Gastroenterology 127 S62 S71 1:CAS:528: DC%2BD2cXhtVGmtb7F 10.1053/j.gastro.2004.09.017 15508105
8. S Saadeh G Cammell WD Carey Z Younossi D Barnes K Easley 2001 The role of liver biopsy in chronic hepatitis C Hepatology 33 196 200 1:STN:280: DC%2BD3M%2FpvV2qug%3D%3D 10.1053/jhep.2001.20534 11124836
9. KA Gebo HF Herlong MS Torbenson MW Jenckes G Chander KG Ghanem, et al. 2002 Role of liver biopsy in management of chronic hepatitis C: a systematic review Hepatology 36 S161 S172 10.1002/hep.1840360721 12407590
10. A Regev M Berho LJ Jeffers C Milikowski EG Molina NT Pyrsopoulos, et al. 2002 Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection Am J Gastroenterol 97 2614 2618 10.1111/j.1572-0241.2002. 06038.x 12385448
11. ML Yu SM Lin CM Lee CY Dai WY Chang SC Chen, et al. 2006 A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy Hepatology 44 1086 1097 1:CAS:528:DC%2BD28Xht1aktL7P 10.1002/hep.21363 17058238
12. E Ono Y Shiratori T Okudaira M Imamura T Teratani F Kanai, et al. 1999 Platelet count reflects stage of chronic hepatitis C Hepatol Res 15 192 200 10.1016/S1386-6346(98)00075-8
13. H Matsumura M Moriyama I Goto N Tanaka H Okubo Y Arakawa 2000 Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment J Viral Hepat 7 268 275 1:STN:280:DC%2BD3cvntVCmsg%3D%3D 10.1046/j.1365-2893.2000.00235.x 10886535
14. A Pohl C Behling D Oliver M Kilani P Monson T Hassanein 2001 Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection Am J Gastroenterol 96 3142 3146 1:CAS:528:DC%2BD3MXpt1Kmtbw%3D 10.1111/j.1572-0241.2001.05268.x 11721762
15. F Degos C Christidis N Ganne-Carrie JP Farmachidi C Degott C Guettier, et al. 2000 Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death Gut 47 131 136 1:STN:280: DC%2BD3czitVOqtw%3D%3D 10.1136/gut.47.1.131 10861275
16. JL Rodriguez-Diaz V Rosas-Camargo O Vega-Vega D Morales-Espinosa A Mendez-Reguera JL Martinez-Tlahuel, et al. 2007 Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study Clin Oncol (R Coll Radiol) 19 197 203 1:STN:280:DC%2BD2s7lvFOmtQ%3D%3D
17. VJ Desmet M Gerber JH Hoofnagle M Manns PJ Scheuer 1994 Classification of chronic hepatitis: diagnosis, grading and staging Hepatology 19 1513 1520 1:STN:280:DyaK2c3ksFWisw%3D%3D 10.1002/hep.1840190629 8188183
18. K Aoyagi C Ohue K Iida T Kimura E Tanaka K Kiyosawa, et al. 1999 Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen J Clin Microbiol 37 1802 1808 1:CAS:528:DyaK1MXjslSrtb8%3D 10325327
19. E Tanaka C Ohue K Aoyagi K Yamaguchi S Yagi K Kiyosawa, et al. 2000 Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA Hepatology 32 388 393 1:CAS:528:DC%2BD3cXlvVyjtLo%3D 10.1053/jhep.2000.9112 10915747
20. P Simmonds EC Holmes TA Cha SW Chan F McOmish B Irvine, et al. 1993 Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region J Gen Virol 74 Pt 11 2391 2399 1:CAS:528:DyaK2cXkvFOhtA%3D%3D 10.1099/0022-1317-74-11-2391 8245854
21. O Ohno M Mizokami RR Wu MG Saleh K Ohba E Orito, et al. 1997 New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a J Clin Microbiol 35 201 207 1:CAS:528:DyaK2sXktVKksA%3D%3D 8968908
22. Y Aizawa Y Shibamoto I Takagi M Zeniya G Toda 2000 Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis Cancer 89 53 59 1:STN:280:DC%2BD3czlslSnsw%3D%3D 10.1002/1097-0142(20000701)89:1<53::AID- CNCR8>3.0.CO;2-6 10897000
23. G Fattovich T Stroffolini I Zagni F Donato 2004 Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 S35 S50 10.1053/j.gastro.2004.09.014 15508101
24. K Kiyosawa T Umemura T Ichijo A Matsumoto K Yoshizawa A Gad, et al. 2004 Hepatocellular carcinoma: recent trends in Japan Gastroenterology 127 S17 S26 10.1053/j.gastro.2004.09.012 15508082
25. J Bruix M Sherman 2005 Management of hepatocellular carcinoma Hepatology 42 1208 1236 10.1002/hep.20933 16250051
26. M Colombo R de Franchis E Del Ninno A Sangiovanni C De Fazio M Tommasini, et al. 1991 Hepatocellular carcinoma in Italian patients with cirrhosis N Engl J Med 325 675 680 1:STN:280:DyaK3MzjtlKktg%3D%3D 10.1056/NEJM199109053251002 1651452
27. H Tsukuma T Hiyama S Tanaka M Nakao T Yabuuchi T Kitamura, et al. 1993 Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1797 1801 1:STN:280:DyaK3s3nsFektg%3D%3D 10.1056/NEJM199306243282501 7684822
28. H Oka A Tamori T Kuroki K Kobayashi S Yamamoto 1994 Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma Hepatology 19 61 66 1:STN:280:DyaK2c7gt1Ojuw%3D%3D 10.1002/hep.1840190111 7506227
29. N Ganne-Carrie C Chastang F Chapel C Munz D Pateron M Sibony, et al. 1996 Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis Hepatology 23 1112 1118 1:STN:280:DyaK283gs1Gnsw%3D%3D 10.1002/hep.510230527 8621142
30. A Sangiovanni E Colombo F Radaelli A Bortoli G Bovo MA Casiraghi, et al. 2001 Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients Am J Gastroenterol 96 1575 1580 1:STN:280:DC%2BD3M3ptF2jtw%3D%3D 10.1111/j.1572-0241.2001.03780.x 11374702
31. K Ikeda Y Arase S Saitoh M Kobayashi T Someya T Hosaka, et al. 2006 Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts J Hepatol 44 1089 1097 1:CAS:528:DC%2BD28XksVaisbw%3D 10.1016/j.jhep.2006.02.008 16618514
32. MG Bruce D Bruden BJ McMahon C Christensen C Homan D Sullivan, et al. 2008 Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C J Viral Hepat 15 179 187 1:STN:280: DC%2BD1c%2FnslertA%3D%3D 10.1111/j.1365-2893.2007.00928.x 18233991
33. K Taketa 1990 Alpha-fetoprotein: reevaluation in hepatology Hepatology 12 1420 1432 1:CAS:528:DyaK3MXkvV2qtbY%3D 10.1002/hep.1840120625 1701754
34. CW Chu SJ Hwang JC Luo CR Lai SH Tsay CP Li, et al. 2001 Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C J Clin Gastroenterol 32 240 244 1:STN:280:DC%2BD3M7mslGrug%3D%3D 10.1097/00004836-200103000-00014 11246354
35. LG Lu MD Zeng MB Wan CZ Li YM Mao JQ Li, et al. 2003 Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters World J Gastroenterol 9 2574 2578 14606100
36. KQ Hu NL Kyulo N Lim B Elhazin DJ Hillebrand T Bock 2004 Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma Am J Gastroenterol 99 860 865 1:CAS:528:DC%2BD2cXlt1CjtbY%3D 10.1111/j.1572-0241.2004.04152.x 15128351
37. P Wilfredo Canchis SA Gonzalez M Isabel Fiel L Chiriboga H Yee BR Edlin, et al. 2004 Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein Liver Int 24 198 203 1:STN:280:DC%2BD2c3ovFGjsQ%3D%3D 10.1111/j.1478-3231.2004.00907.x 15189269
38. AM Di Bisceglie RK Sterling RT Chung JE Everhart JL Dienstag HL Bonkovsky, et al. 2005 Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial J Hepatol 43 434 441 1:CAS:528:DC%2BD2MXntVCkurc%3D 10.1016/j.jhep.2005.03.019 16136646
39. S Nishiguchi T Kuroki S Nakatani H Morimoto T Takeda S Nakajima, et al. 1995 Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1051 1055 1:CAS:528:DyaK2MXpsl2lurY%3D 10.1016/S0140-6736(95)91739-X 7564784
40. ML Yu CF Huang CY Dai JF Huang WL Chuang 2007 Long-term effects of interferon-based therapy for chronic hepatitis C Oncology 72 Suppl 1 16 23 1:CAS:528:DC%2BD2sXhsVels7bJ 10.1159/000111703 18087178
41. Y Imai S Kawata S Tamura I Yabuuchi S Noda M Inada, et al. 1998 Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group Ann Intern Med 129 94 99 1:CAS:528:DyaK1cXlt1emsbk%3D 9669992
42. A Kasahara N Hayashi K Mochizuki M Takayanagi K Yoshioka S Kakumu, et al. 1998 Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 27 1394 1402 1:CAS:528:DyaK1cXjtVSjt7Y%3D 10.1002/hep.510270529 9581697
43. K Ikeda S Saitoh Y Arase K Chayama Y Suzuki M Kobayashi, et al. 1999 Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis Hepatology 29 1124 1130 1:CAS:528:DyaK1MXisVKgsLk%3D 10.1002/hep.510290439 10094956
44. T Okanoue Y Itoh T Kirishima Y Daimon T Toyama A Morita, et al. 2002 Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients Hepatol Res 23 62 77 1:CAS:528: DC%2BD38XltlakurY%3D 10.1016/S1386-6346(02)00016-5 12084557
45. K Hino K Okita 2004 Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C J Antimicrob Chemother 53 19 22 1:CAS:528:DC%2BD3sXhtVShsbrN 10.1093/jac/dkh031 14657083
46. DC Valla M Chevallier P Marcellin JL Payen C Trepo M Fonck, et al. 1999 Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment Hepatology 29 1870 1875 1:CAS:528:DyaK1MXjvFOmsbw%3D 10.1002/hep.510290616 10347132
47. C Camma D Di Bona A Craxi 2004 The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach Curr Pharm Des 10 2123 2130 1:CAS:528:DC%2BD2cXltFCnurs%3D 10.2174/1381612043384321 15279551
48. ML Shiffman CM Hofmann MJ Contos VA Luketic AJ Sanyal RK Sterling, et al. 1999 A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia Gastroenterology 117 1164 1172 1:CAS:528:DyaK1MXnsVCqtro%3D 10.1016/S0016-5085(99)70402-6 10535880
49. DF Stein M Myaing 2002 Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis Dig Dis Sci 47 2686 2690 10.1023/A:1021044803279 12498286
50. S Murashima M Tanaka M Haramaki S Yutani Y Nakashima K Harada, et al. 2006 A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP Dig Dis Sci 51 808 812 1:CAS:528:DC%2BD28XjsFSls7w%3D 10.1007/s10620-006-3211-2 16615008
51. H Yano A Iemura M Haramaki S Ogasawara A Takayama J Akiba, et al. 1999 Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines Hepatology 29 1708 1717 1:CAS:528: DyaK1MXjvFOmsL8%3D 10.1002/hep.510290624 10347112
52. K Tarao Y Rino S Ohkawa A Shimizu S Tamai K Miyakawa, et al. 1999 Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis Cancer 86 589 595 1:CAS:528:DyaK1MXlslSmtr0%3D 10.1002/(SICI)1097-0142(19990815)86:4<589::AID- CNCR7>3.0.CO;2-K 10440686
53. K Tarao Y Rino S Ohkawa S Tamai K Miyakawa H Takakura, et al. 2002 Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis Cancer 94 1787 1795 10.1002/cncr.10391 11920542
54. M Moriyama H Matsumura H Aoki T Shimizu K Nakai T Saito, et al. 2003 Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy Intervirology 46 296 307 1:CAS:528:DC%2BD3sXotVejuro%3D 10.1159/000073209 14555850
55. RF Velazquez M Rodriguez CA Navascues A Linares R Perez NG Sotorrios, et al. 2003 Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis Hepatology 37 520 527 10.1053/jhep.2003.50093 12601348